Top View
- Success for Crizotinib in ALK-Driven Cancer
- Crizotinib Clinical Trials – Currently Ongoing And/Or Enrolling Fact Sheet
- Xalkori, INN-Crizotinib
- Trastuzumab Emtansine Is Active on HER-2 Overexpressing NSCLC Cell
- ALK Inhibitors in Non–Small Cell Lung Cancer: Crizotinib and Beyond Mark M
- Testing for Targeted Therapy of Non-Small-Cell Lung Cancer AHS - M2030
- PF-00299804 Bosutinib Axitinib
- Effect of Tyrosine Kinase Inhibitors on Renal Handling of Creatinine By
- Lorlatinib) Tablets, for Oral Use Interstitial Lung Disease/Pneumonitis: Immediately Withhold Initial U.S
- DRUG NAME: Crizotinib
- Specialty Pharmacy Distribution Network for IBRANCE® (Palbociclib), INLYTA® (Axitinib), XALKORI® (Crizotinib), BOSULIF® (Bosutinib), and SUTENT® (Sunitinib Malate)
- In Gastric Cancer Positive for MET Amplification
- Management of Crizotinib Therapy for ALK-Rearranged Non-Small Cell
- The Potent ALK Inhibitor Brigatinib (AP26113)
- The Use of Crizotinib in Late Stage Lung Cancer Patients with an Abnormal ALK Gene
- Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer
- Specialty Pharmacy Distribution Network for IBRANCE® (Palbociclib), INLYTA® (Axitinib), XALKORI® (Crizotinib), BOSULIF® (Bosutinib), and SUTENT® (Sunitinib Malate)
- Crizotinib Induces PUMA-Dependent Apoptosis in Colon Cancer Cells
- Therapeutic Advances in Oncology
- “I Fight.” “I Was in the Waiting Room
- Product Information
- The Novel VEGF Receptor/MET–Targeted Kinase Inhibitor TAS-115 Has Marked in Vivo Antitumor Properties and a Favorable Tolerability Profile
- Histone Deacetylase Inhibitor Resminostat in Combination with Sorafenib Counteracts Platelet-Mediated Pro-Tumoral Effects In
- Crizotinib with Or Without an EGFR-TKI in Treating EGFR-Mutant
- MET Copy Number Gain Is Associated with Gefitinib Resistance in Leptomeningeal Carcinomatosis of EGFR-Mutant Lung Cancer
- Policy Drug(S) Brief Description of Policy Change UM ONC 1038 Emend (Aprepitant Oral Or Add Exclusion Criteria: 1
- Exploring the Expansion of the Medicines Patent Pool's Mandate To
- ALK and ROS1 As Targeted Therapy Paradigms and Clinical Implications to Overcome Crizotinib Resistance
- June 30, 2021 Total Approvals 269 This Report Will Be Updated January and July of Every Year
- PF-06463922 Is a Potent and Selective Next-Generation ROS1/ALK Inhibitor Capable of Blocking Crizotinib-Resistant ROS1 Mutations
- Therapeutic Strategies to Overcome Crizotinib Resistance in Non-Small Cell Lung Cancers Harboring the Fusion Oncogene EML4-ALK
- Transforming Into Oncology- Sunao Manabe President and COO June 2, 2019 ASCO Investor Relations Presentation, Chicago, IL Forward-Looking Statements
- MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer a C Ibiayi Dagogo-Jack1,2, Satoshi Yoda1,2, Jochen K
- Combination Strategy Targeting VEGF and HGF/C-Met in Human Renal Cell Carcinoma Models
- XALKORI® (Crizotinib)
- Emtansine (T-DM1) Resistance in HER2-Positive Cancer
- Roche to Present New Data from Its Broad Oncology Portfolio at The
- LORBRENA (Lorlatinib) Is a Kinase Inhibitor for Oral Administration
- 82253614.Pdf
- Your Treatment With… XALKORI® (Crizotinib) This Booklet Is Intended for Patients Who Have Been Prescribed XALKORI
- Epithelial Transfer of the Tyrosine Kinase Inhibitors Erlotinib, Gefitinib
- Resistance Mechanisms to Targeted Therapies in ROS1 and ALK Non
- XALKORI (Crizotinib)
- Axitinib and Crizotinib Combination Therapy Inhibits Bone Loss in A
- New Target Therapies in Advanced Non-Small Cell Lung Cancer: a Review of the Literature and Future Perspectives
- Original Article the Effects of the Combination of Imatinib and Crizotinib on Small Cell Lung Cancer Cells Expressing C-Met and C-Kit
- Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14 Mutant NSCLC